Healthcare
Live Price
Offline$0.1295
+24.64% today
Window Change
+355.99%
Window
Jun 23, 2025 → May 15, 2026
Coverage: 225 bars · Jun 23, 2025 → May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Bristol-Myers Squibb Company Ce (CELG-RI) is a Healthcare stock with a market cap of $264.45M. The stock last traded around $0.13 and up 356.0% across the available one-year price window (Jun 23, 2025 → May 15, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +178.7%, a dividend yield of 0.0%. What stands out right now is revenue -0.2%, EPS +178.7%, free cash flow -7.9% with operating margin 34.0% and ROIC 13.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CELG-RI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CELG-RI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CELG-RI Max Drawdown
-64.27%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CELG-RI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$46.4B
+0.5% YoY
FY Net Income
$7.0B
+10.5% YoY
Free Cash Flow
$15.2B
+27.5% YoY
Revenue Growth
-0.2%
EPS Growth
+178.7%
Gross Margin
96.2%
Net Margin
26.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 48.2B | 48.3B | 45.0B | 46.2B | 46.4B |
| Gross Profit | 34.9B | 27.4B | 34.3B | 36.0B | 36.4B |
| Operating Income | 15.1B | 9.7B | 8.2B | 9.1B | 8.5B |
| EBITDA | 19.2B | 3.2B | 19.4B | 19.2B | 20.1B |
| Net Income | 7.1B | -8.9B | 8.0B | 6.3B | 7.0B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 10.2B | 10.3B | 11.5B | 9.1B | 14.0B |
| Total Assets | 90.0B | 92.6B | 95.2B | 96.8B | 109.3B |
| Total Liabilities | 71.5B | 76.2B | 65.7B | 65.7B | 73.3B |
| Shareholder Equity | 18.5B | 16.3B | 29.4B | 31.1B | 35.9B |
| Total Debt | 49.0B | 51.2B | 41.5B | 40.7B | 45.6B |
| Net Debt | 38.8B | 40.9B | 30.0B | 31.6B | 31.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
16.2B
+24.0% YoY
Capital Expenditures
973M
+13.0% YoY
Free Cash Flow
15.2B
+27.5% YoY
Key ratios
Gross Margin
96.2%
Operating Margin
34.0%
Net Margin
26.5%
ROE
61.9%
Debt / Equity
3.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.